Takeda, Kyoto University to End Decade-Long iPS Research Tie-Up

Delayed

Japan Exchange

07:59:00 2026-02-03 pm EST

5-day change

1st Jan Change

5,445.00 JPY

+0.48%

+6.16%

+12.64%

Published on 02/03/2026
at 07:26 pm EST

MT Newswires

© MT Newswires –
2026
07:26pm

Takeda, Kyoto University to End Decade-Long iPS Research Tie-Up

MT

Jan. 30

Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,700 Yen From 5,100 Yen, Keeps at Buy

MT

Jan. 29

Takeda Pharmaceutical Company Limited, Q3 2026 Earnings Call, Jan 29, 2026

Jan. 29

Takeda Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended December 31, 2025

CI

Jan. 29

Takeda Pharmaceutical Fiscal Q3 Core Earnings, Revenue Rise; Full-Year Outlook Updated

MT

Jan. 29

Takeda Pharmaceutical’s Nine-Month Net Profit Gains 2.4%

MT

Jan. 29

Takeda Pharmaceutical Company Limited Revises Consolidated Earnings Guidance for the Fiscal Year 2025

CI

Jan. 29

Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance

DJ

Jan. 27

Cms announces selection of drugs for third cycle of the Medicare drug price negotiation program

RE

Jan. 22

Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-To-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A Content

CI

Jan. 22

Takeda Pharmaceutical Launches Liquid Medicine for Primary Immunodeficiency in US

MT

Jan. 22

Takeda announces US availability of Gammagard Liquid ERC, the only ready-to-use liquid immunoglobulin therapy with low immunoglobulin A content

RE

Jan. 15

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

RE

Jan. 13

Oncolytics Biotech Inc. Appoints Yujun Wu as Vice President, Head of Biostatistics

CI

Jan. 12

Takeda Pharmaceutical Company Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM

Jan. 08

Halozyme Therapeutics, Takeda Collaborate on Vedolizumab Drug Delivery

MT

Jan. 06

Nimbus, Lilly sign deal to develop new oral obesity drug

RE

Jan. 05

Takeda and Protagonist Announce Submission of New Drug Application for Rusfertide for Treatment of Polycythemia Vera

CI

Jan. 05

Takeda Pharmaceutical, Protagonist Submit FDA Application for Rusfertide for Polycythemia Vera Treatment

MT

Dec. 30

XOMA Royalty Amends Takeda Deal, Expects Royalties Tied to Broader Asset Portfolio

MT

Dec. 30

XOMA Royalty Corporation Amends Its Collaboration with Takeda Through Strategic Royalty Share Transaction

CI

Dec. 18

Takeda Pharmaceuticals Shares Rise on Positive Psoriasis Treatment Results

DJ

Dec. 18

Takeda’s AI-crafted psoriasis pill succeeds in late-stage studies

RE

Dec. 18

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday

MT

Dec. 18

Sector Update: Health Care

MT

DurationAuto.2 months3 months6 months9 months1 year2 years5 years10 yearsMax.

PeriodDayWeek

4502: Dynamic Chart

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company’s research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

More about the company

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

More RatingsSellBuy

Last Close Price

5,419.00JPY

Average target price

5,263.07JPY

Spread / Average Target

-2.88%

ConsensusQuarterly revenue – Rate of surprise

OUR EXPERTS ARE HERE FOR YOU

Monday – Friday 9am-12pm / 2pm-6pm GMT + 1

Legal information
|
Cookie settings
|
MarketScreener Blog
|
About us
|
Copyright © 2026 Surperformance SAS. All rights reserved.

Stock quotes are provided by Factset, Morningstar and S&P Capital IQ

Select your edition

All financial news and data tailored to specific country editions